Prolonged Survival of a Patient with Advanced-Stage Combined Hepatocellular-Cholangiocarcinoma.
Chemotherapy
Combined hepatocellular-cholangiocarcinoma
Liver transplantation
Next-generation sequencing
Targeted therapy
Journal
Case reports in gastroenterology
ISSN: 1662-0631
Titre abrégé: Case Rep Gastroenterol
Pays: Switzerland
ID NLM: 101474819
Informations de publication
Date de publication:
Historique:
received:
30
07
2020
accepted:
13
08
2020
entrez:
14
1
2021
pubmed:
15
1
2021
medline:
15
1
2021
Statut:
epublish
Résumé
Combined hepatocellular-cholangiocarcinoma (cHCC/CCA) represents a rare type of primary liver cancer with a very limited prognosis. Although just recently genomic studies have contributed to a better understanding of the disease's genetic landscape, therapeutic options, especially for advanced-stage patients, are limited and often experimental, as no standardized treatment protocols have been established to date. Here, we report the case of a 38-year-old male patient who was diagnosed with extensive intrahepatic cHCC/CCA in an otherwise healthy liver without signs of chronic liver disease. An interdisciplinary stepwise therapeutic approach including locoregional liver-targeted therapy, systemic chemotherapy, liver transplantation, surgical pulmonary metastasis resection, and next-generation sequencing-based targeted therapy led to a prolonged overall survival beyond 5 years with an excellent quality of life. This case report comprises several provocative treatment decisions that are extensively discussed in light of the existing literature on this rare but highly aggressive malignancy.
Identifiants
pubmed: 33442346
doi: 10.1159/000511034
pii: crg-0014-0658
pmc: PMC7772835
doi:
Types de publication
Case Reports
Langues
eng
Pagination
658-667Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Lancet Oncol. 2010 Dec;11(12):1142-8
pubmed: 21071270
World J Surg Oncol. 2019 Feb 27;17(1):43
pubmed: 30813932
J Pathol. 2019 Jun;248(2):164-178
pubmed: 30690729
PLoS One. 2018 Jun 7;13(6):e0198138
pubmed: 29879137
Nat Med. 2016 Nov;22(11):1314-1320
pubmed: 27748748
Hepatobiliary Pancreat Dis Int. 2019 Feb;18(1):12-18
pubmed: 30442549
Radiology. 2010 Apr;255(1):270-7
pubmed: 20308463
Lancet Gastroenterol Hepatol. 2018 May;3(5):337-348
pubmed: 29548617
Cancer Sci. 2018 Aug;109(8):2549-2557
pubmed: 29856900
Hepatol Res. 2005 Jul;32(3):185-95
pubmed: 15978872